BioDrugs

, Volume 27, Issue 3, pp 275–279

Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU

  • Gillian M. Keating
  • Katherine A. Lyseng-Williamson
  • Paul L. McCormack
  • Susan J. Keam
Adis Drug Clinical Q&A

DOI: 10.1007/s40259-013-0024-7

Cite this article as:
Keating, G.M., Lyseng-Williamson, K.A., McCormack, P.L. et al. BioDrugs (2013) 27: 275. doi:10.1007/s40259-013-0024-7

Abstract

Oral dasatinib (Sprycel®) is effective in the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) or imatinib-resistant or imatinib-intolerant chronic-phase, accelerated-phase, or blast-phase CML. In particular, dasatinib is associated with better and faster responses than imatinib in patients with newly diagnosed chronic-phase CML. The response to dasatinib appears to be maintained in the longer-term. Dasatinib has an acceptable tolerability profile; it is associated with myelosuppression, with fluid retention being the most common nonhematologic adverse event. Thus, dasatinib is a highly effective, once-daily therapy for the first-line treatment of patients with chronic-phase CML and for the second-line treatment of imatinib-resistant or imatinib-intolerant CML.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Gillian M. Keating
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  • Paul L. McCormack
    • 1
  • Susan J. Keam
    • 1
  1. 1.AdisNorth ShoreNew Zealand